National Fellows Forum

A program specifically designed to support the professional development of oncology fellows.
Through expert-led panel discussions, presentation opportunities, and peer-to-peer engagement, fellows gain insights that bridge academic training and clinical decision-making.
Fosters a collaborative learning environment that empowers the next generation of oncology leaders.

Events

National Fellows Forum: Breast Cancer

Upcoming Event

National Fellows Forum: Breast Cancer

December 9, 2026 · 900 E. Market Street, San Antonio, TX 78205

National Fellows Forum: Hematology

Upcoming Event

National Fellows Forum: Hematology

December 11, 2026 · New Orleans, Louisiana

Past Events (6)

OncLive National Fellows Forum: Lung CancerJuly 23, 2026 · 21500 Pacific Coast Highway, Huntington Beach, CA
OncLive National Fellows Forum: Lung CancerMay 28, 2026 · Chicago, IL
OncLive National Fellows Forum: GynOncApril 16, 2026 · San Diego, CA
OncLive National Fellows Forum: Genitourinary CancerFebruary 25, 2026 · San Francisco, CA
National Fellows Forum: Breast CancerDecember 8, 2025 · 115 Lexington Ave, San Antonio, TX 78205
National Fellows Forum: Gastrointestinal CancerSeptember 11, 2025 · 700 San Jacinto at 8th St, Austin, TX 78701

Lung Cancer

What Oncology Fellowship Is Really Like: Jonathan Lee, MD, and Chinmay Jani, MD

What Oncology Fellowship Is Really Like: Jonathan Lee, MD, and Chinmay Jani, MD

Tali Azenkot, MD, of UC San Diego

Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC

Hyein Jeon, MD, hematology oncology fellow, Albert Einstein College of Medicine and Montefiore Medical Center

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

Chinmay Jani, MD, University of Miami Sylvester Comprehensive Cancer Center

Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials

Noha Soror, MD, University of Oklahoma College of Medicine

Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer

Robert Cameron, MD, PhD

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

Mitchell Parma, MD

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

Kelsey Pan, MD, MPH

Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

First-in-Human: Jyoti Malhotra, MD, MPH on Phase I Trials, Lung Cancer in 2026, and Yale

Dr William on First-Line EGFR-Mutant NSCLC in AMIGO-1

Dr William on First-Line EGFR-Mutant NSCLC in AMIGO-1

Genitourinary Cancers

Akshit Chitkara, MD

Dr Chitkara on Outcomes With IO Doublet Therapy in ccRCC by Disease Subtype

Jeffrey Zhong, MD, Case Western Reserve University

Dr Zhong on Upfront Dose Reductions of EV-Pembro in Advanced Urothelial Carcinoma

Adanma Ayanambakkam, MD, MS

Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD

Adanma Ayanambakkam, MD, MS,

Dr Ayanambakkam on the Design of the FIT-001 Trial in Renal Cell Carcinoma

Adanma Ayanambakkam, MD, MS

Dr Ayanambakkam on the FIT-001 Study in Renal Cell Carcinoma

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on Safety Data From the Phase 3 LITESPARK-022 Trial in ccRCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on the Phase 3 LITESPARK-022 Trial of Belzutifan Plus Pembrolizumab in ccRCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on Integrating Adjuvant Belzutifan Plus Pembrolizumab into Clinical Practice in RCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on the FDA Approval of Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Benjamin Croll, MD, Fox Chase Cancer Center

Dr Croll on the Development of Biomarkers in RCC

Oncology Fellows